Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: Results of a double-blind, randomized, placebo-controlled study

BJU International

Volumn 83, Issue 3, 1999, Pages 269-273

  Chen, J ^a,b   Wollman, Y ^a   Chernichovsky, T ^a   Iaina, A ^a   Sofer, M ^a   Matzkin, H ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Erectile dysfunction; L arginine; Nitric oxide donor; Oral treatment

Indexed keywords

ARGININE; NITRATE; NITRIC OXIDE DONOR; NITRITE;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOUBLE BLIND PROCEDURE; ERECTILE DYSFUNCTION; HEMODYNAMICS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PENIS; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; URINE;

ADMINISTRATION, ORAL; AGED; ARGININE; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0033035004     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00906.x     Document Type: Article

References (22)

1. 1 Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6
2. 2 Burnett AL, Lowenstein CJ, Bredt DS, Chang TSK, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-3
3. 3 Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4
4. 4 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
5. 5 Brock G, Nunes L, Padma-Nathan H, Boyd S, Lue T. Nitric oxide synthase: a new diagnostic tool for neurogenic impotence. Urology 1993; 42: 412-7
6. 6 Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-4
7. 7 Saez de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-30
8. 8 Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-8
9. 9 Meyer MF, Tahar A, Krah H et al. Intracavernous application of SIN-1 in rabbit and man: functional and toxicological results. Ann Urol 1993; 27: 179-82
10. 10 Truss MC, Becker AJ, Djamilian MH, Stief CG, Jonas U. Role of the nitric oxide donor linsidomine chlorohydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 1994; 44: 553-6
11. 11 Stief CG, Holmquist F, Djamilian M, Krah H, Andersson KE, Jonas U. Preliminary results with the nitric oxide donor linsidomine chlorohydrate in the treatment of human erectile dysfunction. J Urol 1992; 148: 1437-40
12. 12 Wegner HEH, Knispel HH. Effect of nitric oxide-donor, linsidomine chlorohydrate, the treatment of human erectile dysfunction caused by venous leakage. Urology 1993; 42: 409-11
13. 13 Moody JA, Vernet D, Laidlaw S, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term oral administration of l-arginine on the rat erectile response. J Urol 1997; 158: 942-7
14. 14 Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 1994; 6: 33-5
15. 15 O'Leary ME, Fowler FJ and Lenderking WR et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706
16. 16 Koifman B, Wollman Y, Bogomolny N et al. Improvement of cardiac performance by intravenous infusion of l-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995; 26: 1251-6
17. 17 Reynolds JEF ed. Martindale's Nutritional Agents and Vitamins. Arginine. The extra pharmacopia. 31st edn. London, Royal Pharmaceutical Society, Part I. 1996: 1353-54
18. 18 Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose Yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997; 49: 441-4
19. 19 Boolell M, Allen MJ, Ballard SA et al. Sildenafil: an orally active 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52
20. 20 Goldstein I, Lue TF, Padma-Nathan H et al. Oral Sildenafil in the treatment of Erectile Dysfunction. N Engl J Med 1998; 338: 1397-404
21. 21 Clarkson P, Adams MR, Powe AJ et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-93
22. 22 Wheeler MA, Smith SD, Saito N, Foster HE Jr, Weiss RM. Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. J Urol 1997; 158: 2045-50